Mohammad Ahmad Ahamd Odah

Dr. Mohammad Ahmad Ahamd Odah

Biology, Prince Sattam Bin Abdulaziz University, Al Kharj, Ar Riyāḑ, Saudi Arabia
+1
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in AIMS Molecular Science
Verified
Journal Article
Open access
PDF file
Mohammad Ahmad Ahamd OdahMohammad Ahmad Ahamd Odah
Mohammad Ahmad Ahamd Odah
DNA barcoding is a crucial method for assessing and monitoring species diversity amidst escalating threats to global biodiversity. I explore DNA barcoding's potential as a robust and reliable tool for biodiversity assessment. It begins with a comprehensive review of existing literature, delving into the theoretical foundations, methodologies and applications of DNA barcoding. The suitability of various DNA regions, like the COI gene, as universal barcodes are extensively investigated. Additionally, the advantages and limitations of different DNA sequencing technologies and bioinformatics tools are evaluated within the context of DNA barcoding. To evaluate the efficacy of DNA barcoding, diverse ecosystems, including terrestrial, freshwater and marine habitats, are sampled. Extracted DNA from collected specimens undergoes amplification and sequencing of the target barcode region. Comparison of the obtained DNA sequences with reference databases allows for the identification and classification of the sampled organisms. Findings demonstrate that DNA barcoding accurately identifies species, even in cases where morphological identification proves challenging. Moreover, it sheds light on cryptic and endangered species, aiding conservation efforts. I also investigate patterns of genetic diversity and evolutionary relationships among different taxa through the analysis of genetic data. This research contributes to the growing knowledge on DNA barcoding and its applicability for biodiversity assessment. The advantages of this approach, such as speed, accuracy and cost-effectiveness, are highlighted, along with areas for improvement. By unlocking the genetic code, DNA barcoding enhances our understanding of biodiversity, supports conservation initiatives and informs evidence-based decision-making for the sustainable management of ecosystems.

13 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Mohammad Ahmad Ahamd OdahMohammad Ahmad Ahamd Odah
Mohammad Ahmad Ahamd Odah
Background: Drug discovery is an inherently complex, resource-intensive, and time-consuming process, often requiring more than a decade to progress from initial target identification to regulatory approval. Despite technological advancements, high attrition rates and escalating research costs remain significant barriers. Artificial intelligence (AI) has emerged as a transformative force in pharmaceutical research, integrating machine learning, deep learning, and computational biology to revolutionize drug discovery processes. AI-driven models enable faster target identification, molecular docking, lead optimization, and drug repurposing, offering unprecedented efficiency in discovering novel therapeutics. Objective: This systematic review aims to assess the integration of AI in drug discovery, focusing on its applications in target identification, structure-based drug design (SBDD), ligand-based drug design (LBDD), and predictive modeling for clinical trials. The review highlights AI-driven advancements in molecular simulations, de novo drug design, and biomarker identification, providing insights into how AI enhances pharmaceutical innovation. Methods: A comprehensive literature review was conducted using PubMed, Scopus, Web of Science, and Google Scholar, covering research published between 2015 and 2025. Studies evaluating AI applications in computational drug discovery, virtual screening, molecular dynamics, and predictive analytics were included. The methodologies analyzed include convolutional neural networks (CNNs), generative adversarial networks (GANs), reinforcement learning models, and graph neural networks (GNNs). Quality assessment was performed using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias Tool to ensure the reliability of selected studies. Results: AI-powered approaches have significantly improved drug discovery by enhancing target identification, optimizing molecular docking simulations, and accelerating lead optimization. Notable achievements include DeepMind’s AlphaFold in protein structure prediction, Insilico Medicine’s AI-driven fibrosis drug (which entered clinical trials in under 18 months), and BenevolentAI’s identification of Janus kinase inhibitors (JAK) for COVID-19 treatment. AI has also been instrumental in drug repurposing efforts, uncovering new therapeutic potentials for existing FDA-approved drugs. Furthermore, AI-enhanced clinical trial modeling and patient stratification have improved trial efficiency and success rates. Challenges & Future Directions: Despite its potential, AI-driven drug discovery faces challenges, including data bias, lack of interpretability, regulatory barriers, and ethical concerns regarding AI-generated predictions. To maximize AI’s impact, future research should focus on standardizing biological datasets, integrating multi-omics data, and developing explainable AI (XAI) models. The emergence of quantum AI and hybrid AI-physics models presents promising avenues for further accelerating drug discovery. Conclusion: AI is reshaping the landscape of drug discovery, offering unparalleled efficiency in identifying novel drug candidates, optimizing molecular interactions, and predicting clinical outcomes. Its integration with biological data and computational simulations paves the way for the development of personalized and highly effective therapeutics. However, addressing AI-related challenges in transparency, validation, and regulatory compliance remains crucial for translating AI-generated discoveries into clinically viable treatments.

29 April 2024 in ChemistryOpen
Verified
Journal Article
Open access
Farag El-EssawyFarag El-Essawy
Farag El-Essawy
Mohammad Ahmad Ahamd OdahMohammad Ahmad Ahamd Odah
Mohammad Ahmad Ahamd Odah
This study reports the design, synthesis, and antibacterial evaluation of a library of novel polyheterocyclic derivatives featuring a unique fused pyrimidopyridopyrazole moiety. A cyclocondensation reaction between an amino−pyrazolopyridopyrimidine precursor and malonates afforded a series of pyrimidopyridopyrazolopyrimidine derivatives. Further diversification was achieved through nucleophilic cyclocondensation, yielding a collection of complex polyheterocyclic systems encompassing various ring structures. All synthesized compounds were rigorously characterized using spectroscopic techniques and elemental analysis. The antibacterial activity of the newly synthesized compounds was assessed against a panel of Gram‐positive and Gram‐negative bacteria. Notably, several compounds exhibited promising antibacterial activity, highlighting their potential as leads for the development of novel antibiotics.

7 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Mohammad Ahmad Ahamd OdahMohammad Ahmad Ahamd Odah
Mohammad Ahmad Ahamd Odah
Cancer diagnosis stands at the cusp of a profound transformation, driven by the burgeoning capabilities of Artificial Intelligence (AI) and Machine Learning (ML). This comprehensive review illuminates the extraordinary impact of AI and ML in the field, unraveling their multifaceted roles in the realm of oncology. In the arena of cancer diagnosis, AI and ML serve as invaluable allies, empowering healthcare professionals with unparalleled tools for precision and efficiency. Notably, AI's prowess in analyzing medical images, including radiological scans and pathology slides, elevates the early detection of malignancies to new heights. Coupled with its ability to dissect genomic data, AI tailors therapeutic strategies to the individual, promising optimized treatment outcomes. However, the incorporation of AI and ML into clinical practice necessitates a careful navigation of ethical considerations, data privacy, and regulatory landscapes. Safeguarding patient data, ensuring transparency, and addressing algorithmic biases emerge as pivotal challenges that require vigilant attention. Yet, the future of AI and ML in cancer diagnosis is brimming with promise. The integration of multi-modal data, real-time monitoring, and Explainable AI (XAI) methods holds the potential to enrich diagnostic capabilities and engender patient trust. Global collaboration and data sharing initiatives are fostering the development of robust AI models. Furthermore, AI's role in cancer prevention, identifying high-risk individuals and enabling targeted preventive strategies, is poised to revolutionize healthcare. AI and ML are forging a path toward an era of unparalleled accuracy, efficiency, and personalization in cancer diagnosis. Challenges notwithstanding, these technologies bear the promise of fundamentally reshaping patient care, elevating outcomes, and advancing the fight against cancer. The ongoing exploration and responsible implementation of AI and ML in oncology will be pivotal in harnessing their full potential and paving the way for a brighter future for cancer patients.

7 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Mohammad Ahmad Ahamd OdahMohammad Ahmad Ahamd Odah
Mohammad Ahmad Ahamd Odah
Photosynthetic efficiency in crops is a major limiting factor in agricultural productivity and climate resilience. Synthetic biology provides novel approaches to reprogram photosynthesis by engineering carbon fixation pathways, optimizing RuBisCO efficiency, and introducing synthetic carbon-concentrating mechanisms (CCMs). Recent advancements include genome editing for enhanced CO₂ assimilation, incorporation of artificial photosynthetic circuits, and chloroplast genome engineering to improve light-harvesting efficiency. This review explores cutting-edge developments in synthetic biology-driven photosynthetic reprogramming, their potential to increase crop yield, and their role in climate adaptation. We discuss applications in sustainable agriculture, the mitigation of photorespiration, and the biotechnological challenges in translating lab-based innovations into real-world crop systems. Future perspectives include the integration of computational modeling, machine learning-assisted pathway design, and synthetic organelle engineering to further enhance photosynthetic efficiency in food production systems.

8 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Mohammad Ahmad Ahamd OdahMohammad Ahmad Ahamd Odah
Mohammad Ahmad Ahamd Odah
DNA barcoding has emerged as a transformative tool in the realm of biodiversity assessment, facilitating rapid and precise species identification. This review article delves into the evolving landscape of DNA barcoding, with a particular focus on the emergence of mini-barcodes and alternative genes as innovative approaches. Traditional DNA barcoding, anchored in the COI gene, has significantly advanced our understanding of species diversity; however, inherent challenges persist, especially when dealing with degraded samples or taxonomic groups where COI falls short. The introduction of mini-barcodes, characterized by their reduced sequence length, has revolutionized DNA barcoding by expanding its applicability. We explore the utility of mini-barcodes in various scenarios, ranging from DNA extraction from ancient or fragmented specimens to in-field identification using portable sequencing technologies. Case studies and practical insights into their effectiveness are presented, emphasizing their role in overcoming traditional limitations. Alternative genes, a complementary facet of DNA barcoding, offer a novel avenue for enhancing taxonomic resolution and accuracy. This review showcases instances where researchers have harnessed alternative genes to overcome COI's constraints, particularly in diverse taxonomic groups, such as fungi, plants, and microorganisms. The selection of these genes is discussed, along with their potential to uncover hidden biodiversity and improve species delimitation. Examining the broader implications of mini-barcodes and alternative genes, we unveil their pivotal roles in advancing conservation efforts, forensic science, and citizen science initiatives. The adaptable nature of these approaches empowers a diverse range of stakeholders, from scientists conducting critical research to concerned citizens contributing to our collective understanding of the natural world. Looking ahead, we envision an exciting future for DNA barcoding, as these innovations continue to evolve. Integration with cutting-edge sequencing technologies, data analysis methods, and the harnessing of big data hold immense potential. Nonetheless, challenges related to standardization, scalability, and data sharing persist.